Anti-angiogenesis effect of adeno-associated virus-mediated recombinant angiostatin combined with celastrol on intracranial C6 glioma in rats
10.3781/j.issn.1000-7431.2011.10.001
- Author:
Guan WANG
1
Author Information
1. Department of Neurosurgery
- Publication Type:Journal Article
- Keywords:
Angiostatins;
Apoptosis;
Celastrol;
Drug therapy;
Gene therapy;
Glioma
- From:
Tumor
2011;31(10):875-880
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To examine the effects of therapeutic alliance of adeno-associated virus-mediated recombinant angiostatin (AAV-AS) combined with celastrol on tumor growth, microvessel density and apoptosis of intracranial glioma in rats, and to give a prospective of this therapeutic alliance. Methods: A rat intracranial C6 glioma model was established, and then the rats (n=40) were randomly assigned into four groups after 7 days, which were saline control group, AAV-AS group, celastrol group and therapeutic alliance group. The tumor growth was examined by magnetic resonance imaging (MRI) every 7 days, and the volume of tumor was calculated. The rats were killed after 22 days, and the expression of AS protein, the microvessel density and the apoptosis of tumor cells were detected. Results: The expression of AS protein was detectable in AAV-AS group and the therapeutic alliance group, which confirmed the achievement of genetic transduction. The tumor volume, microvessel density and apoptosis index were significantly different in the therapeutic alliance group compared with the other three groups (P<0.05). The therapeutic alliance of AAV-AS combined with celastrol could inhibit the tumor growth, reduce the microvessel density of tumor, and enhance the apoptosis. Conclusion: Gene therapy of AAV-AS combined with celastrol can inhibit glioma growth by inhibiting tumor vasculogenesis. This therapeutic alliance exerts a synergic effect and compensates the shortage of single drug. Copyright© 2011 by TUMOR.
